MindImmune, a drug discovery firm at the University of Rhode Island, is poised to move into clinical trials, pioneering a breakthrough approach to preventing Alzheimer’s disease, focused on blocking aberrant immune cells in the blood from entering the brain
Print subscribers have FREE access to clevelandbanner.com by registering HERE
Non-subscribers have limited monthly access to local stories, but have options to subscribe to print, web or electronic editions by clicking HERE
We are sorry but you have reached the maximum number of free local stories for this month. If you have a website account here, please click HERE to log in for continued access.
If you are a print subscriber but do not have an account here, click HERE to create a website account to gain unlimited free access.
Non-subscribers may gain access by subscribing to any of our print or electronic subscriptions HERE